Intellia Therapeutics (NASDAQ:NTLA) Upgraded to Sell at StockNews.com

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by stock analysts at StockNews.com to a “sell” rating in a report released on Friday.

Several other brokerages have also recently issued reports on NTLA. The Goldman Sachs Group lowered their target price on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Chardan Capital lowered their price target on shares of Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Stifel Nicolaus cut their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, September 11th. Barclays decreased their target price on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $54.00 price target on shares of Intellia Therapeutics in a research report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $57.94.

Intellia Therapeutics Trading Up 4.6 %

NASDAQ:NTLA traded up $0.73 during trading hours on Friday, reaching $16.73. 2,417,141 shares of the company were exchanged, compared to its average volume of 2,854,846. The firm has a market cap of $1.70 billion, a PE ratio of -3.05 and a beta of 1.81. Intellia Therapeutics has a twelve month low of $13.95 and a twelve month high of $34.87. The stock’s 50-day moving average is $19.17 and its 200-day moving average is $22.22.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. The firm’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter last year, the company earned ($1.38) EPS. As a group, research analysts anticipate that Intellia Therapeutics will post -5.21 EPS for the current year.

Insider Activity

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the sale, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC raised its holdings in Intellia Therapeutics by 9.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,894 shares of the company’s stock valued at $245,000 after acquiring an additional 750 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Intellia Therapeutics in the 1st quarter valued at $160,000. Swiss National Bank lifted its position in shares of Intellia Therapeutics by 1.3% during the 1st quarter. Swiss National Bank now owns 167,900 shares of the company’s stock worth $4,619,000 after purchasing an additional 2,200 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Intellia Therapeutics during the first quarter worth $224,000. Finally, ProShare Advisors LLC increased its holdings in Intellia Therapeutics by 11.9% in the first quarter. ProShare Advisors LLC now owns 23,235 shares of the company’s stock valued at $639,000 after buying an additional 2,466 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.